Sparks commentary

Healthcare

Sparks

Isofol (ST: ISOFOL) commences Phase Ib/II arfolitixorin trial
Published by Arron Aatkar, PhD

Isofol has announced that the first patient has been included in the Phase Ib/II trial of arfolitixorin in metastatic colorectal cancer. The trial has been designed to assess the drug candidate as part of the standard 5-FU-based first-line therapy for the condition. The trial is being conducted in two stages. The initial Phase Ib part will evaluate the risk/benefit profile of escalating doses in a new dosing regimen. The second part of the trial will compare the highest dose from Phase Ib with one of the lower doses, with efficacy parameters as primary endpoints.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.